Given the increasingly recognized clinical significance of heparanase, the HS-specific endo-β-d-glucuronidase implicated in multiple aspects of tumor growth and progression [47,48,49,50,51,52], extensive efforts were made to identify agents targeting the HS-degrading activity of this enzyme [53,54,55,56,57]. The gene discussed is HPSE; the disease is neoplasm.